Menu
Back to User profile » Prof. Dr. Nicola Lombardo
Papers published by Prof. Dr. Nicola Lombardo:
Difficult-To-Treat and Severe Asthma: Can Real-World Studies On Effectiveness of Biological Treatments Change the Lives of Patients?
Pelaia C, Giacalone A, Ippolito G, Pastore D, Maglio A, Piazzetta GL, Lobello N, Lombardo N, Vatrella A, Pelaia G
Pragmatic and Observational Research 2024, 15:45-51
Published Date: 11 March 2024
Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
Pelaia C, Lombardo N, Busceti MT, Piazzetta G, Crimi C, Calabrese C, Vatrella A, Pelaia G
Journal of Asthma and Allergy 2021, 14:1165-1172
Published Date: 24 September 2021
Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies
Pelaia C, Vatrella A, Gallelli L, Lombardo N, Sciacqua A, Savino R, Pelaia G
Drug Design, Development and Therapy 2021, 15:1275-1284
Published Date: 23 March 2021
Approach to residual dizziness after successfully treated benign paroxysmal positional vertigo: effect of a polyphenol compound supplementation
Casani AP, Navari E, Albera R, Agus G, Asprella Libonati G, Chiarella G, Lombardo N, Marcelli V, Ralli G, Scotto di Santillo L, Teggi R, Viola P, Califano L
Clinical Pharmacology: Advances and Applications 2019, 11:117-125
Published Date: 1 August 2019
Role of biologics in severe eosinophilic asthma – focus on reslizumab
Pelaia G, Vatrella A, Busceti MT, Gallelli L, Preianò M, Lombardo N, Terracciano R, Maselli R
Therapeutics and Clinical Risk Management 2016, 12:1075-1082
Published Date: 1 July 2016
Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
Pelaia G, Vatrella A, Busceti MT, Gallelli L, Calabrese C, Terracciano R, Lombardo N, Maselli R
Therapeutics and Clinical Risk Management 2015, 11:1563-1572
Published Date: 8 October 2015